| |
n (%)
|
|---|
|
Age at diagnosis
| |
|
≤50 years
|
133 (46)
|
|
>50 years
|
158 (54)
|
|
Race
| |
|
Caucasian
|
239 (82)
|
|
African-American
|
52 (18)
|
|
Stage and node status
| |
|
Stage 1
|
82 (28)
|
|
Stage 2 negative
|
57 (20)
|
|
Stage 2 positive
|
87 (30)
|
|
Stage 3
|
48 (16)
|
|
Stage 4
|
17 (6)
|
|
Estrogen receptor status
| |
|
Positive
|
176 (64)
|
|
Negative
|
101 (36)
|
|
Progesterone receptor status
| |
|
Positive
|
128 (46)
|
|
Negative
|
148 (54)
|
|
Treatment
| |
|
Chemotherapy only
|
95 (33)
|
|
Radiation only
|
25 (9)
|
|
Chemotherapy/radiation
|
54 (19)
|
|
radiation/tamoxifen
|
36 (12)
|
|
Chemotherapy/tamoxifen
|
44 (16)
|
|
Chemotherapy/radiation/tamoxifen
|
35 (12)
|
